Subscribe To
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent ...
November 3, 2023, 11:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potential...
November 3, 2023, 8:05 pm
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial...
November 3, 2023, 8:01 pm
Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...
October 25, 2023, 9:05 am
Olema oncology announces positive phase 2 monotherapy clinical study results for palazestrant
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PF...
October 22, 2023, 6:55 am
Olema oncology announces phase 2 monotherapy clinical results to be presented at the 2023 esmo congress
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor ...
October 16, 2023, 11:02 am
Harpoon therapeutics to present interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company deve...
October 9, 2023, 4:17 pm
Artios to present initial phase 1 clinical monotherapy data for atr inhibitor art0380 in advanced solid tumors at the european society of medical oncology congress 2023
ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replica...
October 5, 2023, 12:00 pm
Acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at th
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clini...
September 19, 2023, 8:32 pm
Cyteir: although the company is winding down, the lead asset had promise
Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 in...
September 18, 2023, 5:32 pm
Eu recommends approval of astrazeneca and daiichi's drug for a type of lung cancer
AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a ...
September 15, 2023, 10:17 am
Werewolf therapeutics reports second quarter 2023 financial results and provides business update
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human cl...
August 10, 2023, 11:10 am
P2y12 inhibitor monotherapy better than aspirin for secondary prevention in cad patients, finds meta-analysis
The patient-level meta-analysis of seven randomized trials, called PANTHER, showed that P2Y12 inhibitor monoth...
July 18, 2023, 2:44 pm
Kura oncology presents late-breaking clinical data for menin inhibitor ziftomenib at 2023 european hematology association (eha) congress
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 c...
June 11, 2023, 7:45 am
Verastem: updated avutometinib data brings my position out of mothballs
Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or i...
June 11, 2023, 4:20 am